Recombinant
RabMAb

Recombinant Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381)

Reviews (4) Submit a question References (14)

Overview

  • Product name

    Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)]
    See all Alpha-synuclein primary antibodies

  • Description

    Rabbit monoclonal [MJF-R13 (8-8)] to Alpha-synuclein (phospho S129)

  • Host species

    Rabbit

  • Specificity

    ab168381 only detects alpha Synuclein phosphorylated on Ser129.

  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC/IF,IHC-P or IP

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Synthetic peptide within Human Alpha-synuclein (phospho S129). The exact sequence is proprietary.
    Database link: P37840

  • Positive control

    • Recombinant alpha-synuclein, expressed in BL21 bacterial cells in the presence of Human Polo-Like Kinase 2; HEK whole cell lysates, stably-transfected with Polo-Like Kinase 2 and alpha Synuclein.

  • General notes

    Alpha-synuclein was the first gene to be linked to Parkinson’s disease (PD) and remains the most promising link to PD pathogenesis, where there is genetic evidence that it may play a causal role. In the brain, alpha-synuclein is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
    Recent studies also indicate that alpha-synuclein undergoes post-translational modification. Though the role of many of these modifications is still under investigation, phosphorylation at Serine 129 may affect alpha-synuclein aggregations and may also serve as marker of disease pathogenesis. With the advent of this phospho-specific Serine 129 antibody, The Michael J. Fox Foundation hopes to ensure that the putative role of this modification can be further examined by all researchers.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties

Applications

Our Abpromise guarantee covers the use of ab168381 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Predicted molecular weight: 14 kDa.
  • Application notes
    Is unsuitable for Flow Cyt,ICC/IF,IHC-P or IP.

    • Target

    • Function

      May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.

    • Tissue specificity

      Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.

    • Involvement in disease

      Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
      Parkinson disease 1
      Parkinson disease 4
      Dementia Lewy body

    • Sequence similarities

      Belongs to the synuclein family.

    • Domain

      The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.

    • Post-translational
      modifications

      Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
      Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
      Ubiquitinated. The predominant conjugate is the diubiquitinated form.
      Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.

    • Cellular localization

      Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons.
    • Information by UniProt

    • Database links

      • Alternative names

        • Alpha synuclein antibody
        • Alpha-synuclein antibody
        • Alpha-synuclein, isoform NACP140 antibody
        • alphaSYN antibody
        • MGC105443 antibody
        • MGC110988 antibody
        • MGC127560 antibody
        • MGC64356 antibody
        • NACP antibody
        • Non A beta component of AD amyloid antibody
        • Non A4 component of amyloid antibody
        • Non A4 component of amyloid precursor antibody
        • Non-A beta component of AD amyloid antibody
        • Non-A-beta component of alzheimers disease amyloid , precursor of antibody
        • Non-A4 component of amyloid precursor antibody
        • Non-A4 component of amyloid, precursor of antibody
        • OTTHUMP00000218549 antibody
        • OTTHUMP00000218551 antibody
        • OTTHUMP00000218552 antibody
        • OTTHUMP00000218553 antibody
        • OTTHUMP00000218554 antibody
        • PARK 1 antibody
        • PARK 4 antibody
        • PARK1 antibody
        • PARK4 antibody
        • Parkinson disease (autosomal dominant, Lewy body) 4 antibody
        • Parkinson disease familial 1 antibody
        • SNCA antibody
        • Snca synuclein antibody
        • Snca synuclein, alpha (non A4 component of amyloid precursor) antibody
        • SYN antibody
        • Synuclein alpha antibody
        • Synuclein alpha 140 antibody
        • Synuclein, alpha (non A4 component of amyloid precursor) antibody
        • SYUA_HUMAN antibody
        see all

      Images

      • Western blot - Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381)
        Western blot - Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381)Image courtesy of Mr. Chun Chau SUNG
        Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) at 1/2000 dilution + Mouse cortical neuron lysate at 30 µg

        Secondary
        Goat anti-rabbit IgG (H+L) HRP

        Developed using the ECL technique.

        Predicted band size: 14 kDa


        Exposure time: 5 minutes


        Lysate prepared in PBS + 1% Triton X-100. Membrane fixed with 0.4% PFA in PBS for 30 min prior to blocking.

        Primary incubation for 12 hours at 4°C.

        See Abreview

      • Western blot - Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381)
        Western blot - Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381)This image is courtesy of Drs. Shyra Gardai and Jennifer Johnston (Elan Pharmaceuticals)
        All lanes : Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) at 1/1000 dilution

        Lane 1 : Recombinant alpha Synuclein expressed in BL21 bacterial cells
        Lane 2 : Recombinant alpha Synuclein expressed in BL21 bacterial cells, in the presence of Human Polo-Like Kinase 2
        Lane 3 : HEK whole cell lysates, stably-transfected with Polo-Like Kinase 2 and alpha Synuclein

        Predicted band size: 14 kDa

      References

      This product has been referenced in:

      • Hu D  et al. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity. Acta Neuropathol 137:939-960 (2019). Read more (PubMed: 30877431) »
      • Herrera-Vaquero M  et al. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent a-synuclein in experimental multiple system atrophy. Biochim Biophys Acta Mol Basis Dis 1865:165513 (2019). Read more (PubMed: 31319154) »
      See all 14 Publications for this product

      Publishing research using ab168381? Please let us know so that we can cite the reference in this datasheet.

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review Submit a question

      1-4 of 4 Abreviews or Q&A

      Western blot abreview for Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)]

       Good
      Abreviews
      abreview image
      Application
      Western blot
      Sample
      Mouse Tissue lysate - whole (Mouse brain lysate)
      Gel Running Conditions
      Reduced Denaturing (12%)
      Loading amount
      20 µg
      Specification
      Mouse brain lysate
      Blocking step
      BSA as blocking agent for 12 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C
      Read More

      Abcam user community

      Verified customer

      Submitted Oct 08 2018

      Immunohistochemistry (PFA perfusion fixed frozen sections) abreview for Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)]

       Excellent
      Abreviews
      abreview image
      Application
      Immunohistochemistry (PFA perfusion fixed frozen sections)
      Sample
      Mouse Tissue sections (Brain)
      Antigen retrieval step
      None
      Permeabilization
      No
      Specification
      Brain
      Blocking step
      Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
      Fixative
      Paraformaldehyde
      Read More

      María Izco

      Verified customer

      Submitted Feb 22 2018

      Western blot abreview for Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)]

       Excellent
      Abreviews
      abreview image
      Application
      Western blot
      Sample
      Mouse Cell lysate - whole cell (Cortical neuron)
      Gel Running Conditions
      Reduced Denaturing
      Loading amount
      30 µg
      Specification
      Cortical neuron
      Blocking step
      Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
      Read More

      Mr. Chun Chau SUNG

      Verified customer

      Submitted Dec 06 2017

      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) abreview for Anti-alpha Synuclein (phospho S129) antibody [MJF-R13 (8-8)]

       Excellent
      Abreviews
      abreview image
      Application
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
      Sample
      Mouse Tissue sections (Intestine)
      Antigen retrieval step
      Heat mediated - Buffer/Enzyme Used: citrate
      Permeabilization
      Yes - triton X100
      Specification
      Intestine
      Blocking step
      Serum as blocking agent for 30 minute(s) · Concentration: 4% · Temperature: 25°C
      Fixative
      Paraformaldehyde
      Read More

      Abcam user community

      Verified customer

      Submitted Jul 18 2016

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com